| Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 16751154 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Rheumatoid arthritis (RA) has severe and lasting effects on quality of life. This review (1) describes the disease progression, disability, and joint destruction that seriously alter a patient's quality of life, and (2) explains how the interleukin-1 receptor antagonist (IL-1Ra), anakinra, retards the progress of disease, thereby improving outcomes. Relevant articles were reviewed with a focus on RA, anakinra, and functional and quality-of-life outcomes. In randomized, controlled trials, the IL-1Ra anakinra provided meaningful benefits for patients with active RA, such as decreased signs and symptoms of disease, slower radiographic disease progression, reduced disability, and improved health-related quality of life. The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life. |
| | |
Authors:
|
Arthur Kavanaugh |
Related Documents
:
|
15034234 - Soluble transferrin receptor and its ratio to erythroblasts in bone marrow may be a new... 3114874 - Acetylator phenotypes in rheumatoid arthritis patients with or without adverse drug rea... 11710704 - Ability of the american college of rheumatology 1987 criteria to predict rheumatoid art... 2121924 - Elevated soluble cd8 in the synovial fluid from patients with rheumatoid arthritis. 21483174 - Upregulation of monocyte tissue factor activity is significantly associated with caroti... 6368084 - A staged papineau protocol for chronic osteomyelitis. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Advances in therapy Volume: 23 ISSN: 0741-238X ISO Abbreviation: Adv Ther Publication Date: 2006 Mar-Apr |
Date Detail:
|
Created Date: 2006-06-05 Completed Date: 2006-07-05 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 208-17 Citation Subset: T |
Affiliation:
|
Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093-0943, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antirheumatic Agents
/
administration & dosage,
therapeutic use* Arthritis, Rheumatoid / drug therapy*, psychology Humans Interleukin 1 Receptor Antagonist Protein Quality of Life* Randomized Controlled Trials as Topic Receptors, Interleukin-1 / antagonists & inhibitors* Recombinant Proteins / administration & dosage, therapeutic use* Sialoglycoproteins / administration & dosage, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents; 0/IL1RN protein, human; 0/Interleukin 1 Receptor Antagonist Protein; 0/Receptors, Interleukin-1; 0/Recombinant Proteins; 0/Sialoglycoproteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of det...
Next Document: Autologous platelet-rich plasma for wound and osseous healing: a review of the literature and commer...